Timing matters: study seeks best moment for PSMA scans after hormone therapy

NCT ID NCT05919329

Recruiting now Knowledge-focused Sponsor: OHSU Knight Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how hormonal therapy changes PSMA levels in men with prostate cancer, both in early and advanced stages. Researchers will use PSMA PET scans at different times after starting therapy to see when the scan is most accurate for staging the cancer. The goal is to improve the timing of these scans to better guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Piflufolastat F-18 (a radioactive tracer used in PSMA PET scans)
What this could lead to: If successful, this could help doctors schedule PSMA PET scans more accurately, improving tumor staging and treatment planning for prostate cancer patients.
What could go wrong: This is a small, early-phase observational study focused on timing, not a treatment. Results may not change clinical practice immediately or apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CASTRATION SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma prostate adenocarcinoma prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CASTRATION SENSITIVE PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER PROSTATE ADENOCARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

OHSU Knight Cancer Institute
RECRUITING

Portland, Oregon, 97239, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.